Coherus OncologyFRA:8C5 -4.27%45 Quick Ratio is 1.50 as of Mar. 2026, which is 44% below its 10-year median of 2.68. GuruFocus rates FRA:8C5 with a GF Score™ of 45/100 and a GF Value™ of €0.69 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,412 Biotechnology companies, Coherus Oncology ranks worse than 72.66% on this metric.
Coherus Oncology has a quick ratio of 1.50. It generally indicates good short-term financial strength.
The historical rank and industry rank for Coherus Oncology's Quick Ratio or its related term are showing as below:
FRA:8C5'
s Quick Ratio Range Over the Past 10 Years
Min: 1.05 Med: 2.68 Max: 7.78
Current: 1.5
During the past 13 years, Coherus Oncology's highest Quick Ratio was 7.78. The lowest was 1.05. And the median was 2.68.
FRA:8C5's Quick Ratio is ranked worse than 72.66% of 1412
companies
in the Biotechnology industry
Industry Median: 3.6
vs FRA:8C5: 1.50
Coherus Oncology (FRA:8C5) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Coherus Oncology Quick Ratio Related Terms
Coherus Oncology Quick Ratio Historical Data
* Premium members only.
The historical data trend for Coherus Oncology's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:8C5 vs TARA, KPTI, CNTN: Quick Ratio Comparison
For the Biotechnology subindustry, Coherus Oncology's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Coherus Oncology Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Coherus Oncology's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Coherus Oncology's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Coherus Oncology's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Coherus Oncology (FRA:8C5) has a Quick Ratio of 1.50 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Coherus Oncology and its competitors. This is 44% below median its historical median of 2.68. Over the past decade, Coherus Oncology's Quick Ratio has ranged from 1.05 to 7.78. According to the industry distribution chart, Coherus Oncology ranks #1026 out of 1412 companies in the Biotechnology industry, placing it in the top 72.7%.
Is Coherus Oncology's Quick Ratio too high?
Coherus Oncology's current Quick Ratio of 1.50 is 44% below median its 10-year median of 2.68. Over the past 10 years, this metric has ranged from a low of 1.05 to a high of 7.78. The Biotechnology industry median Quick Ratio is 3.60. Coherus Oncology's value of 1.50 is 58.3% below this industry median. Based on the distribution chart, Coherus Oncology ranks #1026 out of 1412 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Coherus Oncology has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Coherus Oncology's Quick Ratio compare to TARA and KPTI?
According to the Biotechnology industry distribution chart, Coherus Oncology ranks #1026 out of 1412 companies for Quick Ratio. This places Coherus Oncology in the lower half of its industry. The industry median Quick Ratio is 3.60. Coherus Oncology's value of 1.50 is 58.3% below this benchmark. Historically, Coherus Oncology's own Quick Ratio has ranged from 1.05 to 7.78 over the past decade. While the company's 10-year median is 2.68 vs. the industry median of 3.60, Coherus Oncology has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,412 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Coherus Oncology's current Quick Ratio of 1.50 is 58.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Coherus Oncology and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Coherus Oncology's current Quick Ratio is 1.50, which is 44% below median its own 10-year median of 2.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coherus Oncology stock overvalued right now?
Based on GuruFocus' analysis, Coherus Oncology (FRA:8C5) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.69, compared to a current price of €1.26 — trading 82.2% above its estimated fair value. The current Quick Ratio is 1.50, which is 44% below median its 10-year median of 2.68 and 58.3% below the Biotechnology industry median of 3.60. Coherus Oncology's overall GF Score™ is 45/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Coherus Oncology (FRA:8C5), the current Quick Ratio is 1.50 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Coherus Oncology (FRA:8C5) Overvalued in 2026?
Based on GuruFocus' analysis, Coherus Oncology stock appears to be overvalued.
The current stock price of €1.26 is trading 82.2% above its estimated GF Value™ of €0.69.
GuruFocus considers Coherus Oncology to be Significantly Overvalued.
Key valuation signals for FRA:8C5:
Quick Ratio: 1.50 (44% below median its 10-year median of 2.68)
GF Value™: €0.69 vs. price of €1.26 (82.2% above fair value)
Industry Position: 58.3% below the Biotechnology median (#1026 of 1412)
No single metric tells the full story. See the FRA:8C5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.
45GF Score
Get the complete analysis for FRA:8C5
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:8C5 has been successfully added to your 
